Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Welichem Biotech, a biotechnology company developing therapeutic drugs for autoimmune disease and cancer, completed two Phase II clinical trials with its lead candidate, WBI-1001 on psoriasis and atopic dermatitis.
Subscribe to our email newsletter
Both studies were 12-week, double-blinded, placebo-controlled clinical trials conducted under the regulatory guidelines of Health Canada.
Based on analysis of the data, both the primary and secondary efficacy and safety endpoints were met in both studies.
In February 2010, Welichem had begun enrolling patients in the Phase IIa clinical trial with WBI-1001.
The objectives of the trial were to evaluate the efficacy of the WBI-1001 cream in comparison to the vehicle, and also to evaluate the safety and tolerability of the cream in patients with psoriasis.